Item 3.02. Unregistered Sales of Equity Securities.
On September 21, 2020, Precigen, Inc. (the "Company") issued an aggregate of
6,293,402 shares (the "Conversion Shares") of the Company's common stock
("Common Stock") to two entities affiliated with Harvest Capital Strategies, LLC
(the "Harvest Funds") upon conversion of the outstanding principal balance and
accrued and unpaid interest on convertible promissory notes (the "Notes") issued
by the Company's wholly owned subsidiary Precigen ActoBio, Inc. ("ActoBio") on
September 6, 2018, at a conversion price of $5.0572 per Conversion Share,
reflecting the volume weighted average price of the Common Stock for the 30
consecutive trading days ended September 4, 2020. As previously disclosed, the
Notes were issued with an aggregate principal amount of $30 million in
connection with the acquisition by ActoBio of equity interests in CRS Bio, Inc.,
Genten Therapeutics, Inc. and Relieve Genetics, Inc. The notes had a maturity
date of September 6, 2020, accrued interest at 3.0% compounded annually, and
were payable upon maturity in cash or, at ActoBio's election, shares of Common
Stock.
The issuance of the Conversion Shares was deemed exempt from registration under
the Securities Act of 1933, as amended (the "Securities Act"), in reliance on
Section 4(a)(2) of the Securities Act as a transaction not involving a public
offering.
Item 5.02. Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.
On September 24, 2020, the Board of Directors of the Company (the "Board"), upon
the recommendation of the Compensation Committee of the Board (the "Committee"),
which was made in consultation with F. Daniel Siciliano, the Committee's
independent compensation consultant, approved a new compensation arrangement for
Randal J. Kirk, the Company's Executive Chairman. Mr. Kirk remains the Executive
Chairman of the Company, but as of September 24, 2020 is no longer an employee
or executive officer of the Company. The new arrangement consists of the
following elements beginning with calendar year 2021:
• an annual retainer of $100,000, payable in cash or, at Mr. Kirk's
election, shares of Common Stock, valued at the fair market value of the
Common Stock on the grant date (the "FMV");
• an annual grant of fully vested options to purchase shares of Common
Stock, having a grant date fair value of $250,000, an exercise price per
share equal to the FMV, and a term of 10 years from the grant date; and
• an annual grant of restricted stock units, having a grant date fair value
of $250,000, vesting in full on the first anniversary of the grant date,
subject to Mr. Kirk's continued Board service through the vesting date.
The Board also approved prorated compensation consistent with the foregoing
elements for the nine months of 2020 not covered by Mr. Kirk's previous
compensation arrangement with the Company, which expired on March 31, 2020.
Equity awards granted to Mr. Kirk pursuant to the terms of this arrangement will
be granted under the Company's 2019 Incentive Plan for Non-Employee Service
Providers and the forms of award agreements used for the Company's other
director awards.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses